Patents by Inventor Roche Glycart AG

Roche Glycart AG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fusion Constructs and Use of Same to Produce Antibodies with Increased Fc Receptor Binding Affinity and Effector Function
    Publication number: 20140073005
    Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to nucleic acid molecules, including fusion constructs, having catalytic activity and the use of same in glycosylation engineering of host cells to generate polypeptides with improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Application
    Filed: February 5, 2013
    Publication date: March 13, 2014
    Applicant: ROCHE GLYCART AG
    Inventor: ROCHE GLYCART AG
  • COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH BENDAMUSTINE
    Publication number: 20140044705
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with bendamustine for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and bendamustine.
    Type: Application
    Filed: March 6, 2013
    Publication date: February 13, 2014
    Applicant: ROCHE GLYCART AG
    Inventor: ROCHE GLYCART AG
  • COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH FLUDARABINE AND/OR MITOXANTRONE
    Publication number: 20140010804
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone.
    Type: Application
    Filed: January 18, 2013
    Publication date: January 9, 2014
    Applicant: ROCHE GLYCART AG
    Inventor: Roche Glycart AG
  • Bispecific Anti ErbB2/Anti cMet Antibodies
    Publication number: 20130273054
    Abstract: The present invention relates to bispecific antibodies against human ErbB-2 and against human C-met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
    Type: Application
    Filed: April 10, 2013
    Publication date: October 17, 2013
    Applicant: ROCHE GLYCART AG
    Inventor: ROCHE GLYCART AG
  • Humanized Anti-CDCP1 Antibodies
    Publication number: 20130209455
    Abstract: The present invention relates to humanized antibodies against human CDCP1 (anti-CDCP1 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: December 20, 2012
    Publication date: August 15, 2013
    Applicant: Roche Glycart AG
    Inventor: Roche Glycart AG
  • PREDICTIVE BIOMARKER FOR CANCER TREATMENT WITH ADCC-ENHANCED ANTIBODIES
    Publication number: 20130195854
    Abstract: The present invention is directed to methods for identifying which patients diagnosed with cancer will most benefit from treatment with an anti-cancer therapy comprising an ADCC-enhanced antibody.
    Type: Application
    Filed: January 29, 2013
    Publication date: August 1, 2013
    Applicant: ROCHE GLYCART AG
    Inventor: ROCHE GLYCART AG
  • Bispecific Anti ErbB1 / Anti cMet Antibodies
    Publication number: 20130156772
    Abstract: The present invention relates to bispecific antibodies against human ErbB-1 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
    Type: Application
    Filed: February 22, 2013
    Publication date: June 20, 2013
    Applicant: ROCHE GLYCART AG
    Inventor: Roche Glycart AG